KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.56
+0.03 (+6.44%)
Open$0.56
Previous Close$0.53
Day High$0.60
Day Low$0.47
52W High$2.06
52W Low$0.28
Volume—
Avg Volume305.8K
Market Cap18.16M
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,707.1% upside
Current
$0.56
$0.56
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 437.7K | 3.90M | 3.72M |
| Net Income | -434,822,234 | 467.4K | 601.6K |
| Profit Margin | -14,394.0% | 12.0% | 16.2% |
| EBITDA | -434,805,527 | 1.16M | 1.10M |
| Free Cash Flow | — | 801.3K | 617.9K |
| Rev Growth | — | +18.2% | +4.0% |
| Debt/Equity | — | 0.89 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |